| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Jun―24 |
Thiazole-fused thiazoliniums with ketone warheads as covalent inhibitors targeting Cys44 of SARS-CoV-2 3CLpro |
Qizhen Cao, Zhaoqin Zhang, Guanghao Zhu, Sanfeng Dong, Xue Sun, Yuqing Song, Ya Zhang, Tingting Cai, Xinben Zhang, Yong Zhang, Zhijian Xu, Ruisheng Xiong, Weiliang Zhu, Guangbo Ge, Bo Li |
| 2 |
[GO] |
2023―May―19 |
Serum butyrylcholinesterase as a marker of COVID-19 mortality: Results of the monocentric prospective observational study |
Lucia Markuskova, Zuzana Javorova Rihova, Tomas Fazekas, Anna Martinkovicova, Martina Havrisko, Dominika Dingova, Maria Solavova, Daria Rabarova, Anna Hrabovska |
| 3 |
[GO] |
2023―Feb―22 |
Investigating the competition between ACE2 natural molecular interactors and SARS-CoV-2 candidate inhibitors |
Edoardo Milanetti, Mattia Miotto, Leonardo Bo’, Lorenzo Di Rienzo, Giancarlo Ruocco |
| 4 |
[GO] |
2023―Jan―13 |
Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design |
Hai Ping Shao, Tian Hua Wang, Hong Lin Zhai, Ke Xin Bi, Bing Qiang Zhao |
| 5 |
[GO] |
2023―Jan―11 |
Multi-target activity of copper complexes; antibacterial, DNA binding, and molecular docking with SARS-CoV-2 receptor |
P. Arthi, M. Dharmasivam, B. Kaya, Kalilur Rahiman A |
| 6 |
[GO] |
2022―Nov―03 |
Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation |
J.A. Rodriguez, J. Gonzalez, C.E. Arboleda-Bustos, N. Mendoza, C. Martinez, A. Pinzon |
| 7 |
[GO] |
2022―Sep―15 |
Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches |
Esley S. Santos, Priscila C. Silva, Paulo S.A. Sousa, Cristhyane C. Aquino, Gabriella Pacheco, Luiz F.L.S. Teixeira, Alyne R. Araujo, Francisca B.M. Sousa, Romulo O. Barros, Ricardo M. Ramos, Jefferson A. Rocha, Lucas A.D. Nicolau, Jand V.R. Medeiros |
| 8 |
[GO] |
2022―Sep―13 |
Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection |
Amul S. Bahl, Vipin Kumar Verma, Jagriti Bhatia, Dharamvir Singh Arya |
| 9 |
[GO] |
2022―Aug―11 |
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir |
Qingchen Zhang, Philip W. Melchert, John S. Markowitz |
| 10 |
[GO] |
2022―May―31 |
Pharmacology of COVID-19 |
Antoni Sureda, Solomon Habtemariam, Seyed M. Nabavi |
| 11 |
[GO] |
2022―May―20 |
TRPC6 is altered in COVID-19 pneumonia |
Gina Leidinger, Fidelis Flockerzi, Johannes Hohneck, Rainer M. Bohle, Armin Fieguth, Thomas Tschernig |
| 12 |
[GO] |
2022―Apr―22 |
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19 |
Xiuge Gao, Xian Jing, Junqi Wang, Yuling Zheng, Yawei Qiu, Hui Ji, Lin Peng, Shanxiang Jiang, Wenda Wu, Dawei Guo |
| 13 |
[GO] |
2022―Mar―21 |
Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre / Pro-biotics in manipulating microflora |
Khalid Saad Alharbi, Yogendra Singh, Waleed Hassan almalki, Sushama Rawat, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Imran Kazmi, Fahad A. Al-Abbasi, Sami I. Alzarea, Sachin Kumar Singh, Shvetank Bhatt, Dinesh Kumar Chellappan, Kamal Dua, Gaurav Gupta |
| 14 |
[GO] |
2022―Jan―26 |
The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications |
Konstantinos I. Papadopoulos, Warachaya Sutheesophon, Tar-Choon Aw |
| 15 |
[GO] |
2022―Jan―07 |
Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma |
Xiaoyan Ding, Nan Ye, Minyue Qiu, Hongxia Guo, Junjie Li, Xiaoyang Zhou, Maocheng Yang, Jing Xi, Yongjie Liang, Yuanxin Gong, Jintao Li |
| 16 |
[GO] |
2021―Dec―09 |
Comparisons of the immunological landscape of COVID-19 patients based on sex and disease severity by multi-omics analysis |
Tianfang Zhang, Zeinab Abdelrahman, Qian Liu, Xiaosheng Wang, Zuobing Chen |
| 17 |
[GO] |
2021―Nov―03 |
Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation |
Robin Augustine, Abhilash S, Ajisha Nayeem, Shaheen Abdul Salam, Priya Augustine, Pan Dan, Pablo Monteiro, Fatima Mraiche, Carmine Gentile, Philip M. Hansbro, Lana McClements, Anwarul Hasan |
| 18 |
[GO] |
2021―Sep―11 |
Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19 |
Shalki Choudhary, Kajal Sharma, Pankaj Kumar Singh |
| 19 |
[GO] |
2021―Jul―23 |
Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients |
Rezwanuzzaman Laskar, Safdar Ali |
| 20 |
[GO] |
2021―Jul―17 |
Computational analysis of TMPRSS2 expression in normal and SARS-CoV-2-infected human tissues |
Wenxiu Cao, Qiushi Feng, Xiaosheng Wang |
| 21 |
[GO] |
2021―Jun―22 |
TRP channels in COVID-19 disease: Potential targets for prevention and treatment |
Sahar M. Jaffal, Manal A. Abbas |
| 22 |
[GO] |
2021―May―13 |
A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics |
Krishnan Anand, Chithravel Vadivalagan, Jitcy Saji Joseph, Sachin Kumar Singh, Monica Gulati, Mohd Shahbaaz, Magda H. Abdellattif, Parteek Prasher, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua |
| 23 |
[GO] |
2021―May―08 |
Elucidating of oxidative distress in COVID-19 and methods of its prevention |
Anna-Maria Barciszewska |
| 24 |
[GO] |
2021―Apr―20 |
Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles |
Amgad M. Rabie |
| 25 |
[GO] |
2021―Mar―30 |
Role of phytoconstituents in the management of COVID-19 |
Amiya Das, Deepti Pandita, Gaurav Kumar Jain, Pallavi Agarwal, Ajmer Singh Grewal, Roop K. Khar, Viney Lather |
| 26 |
[GO] |
2021―Feb―18 |
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis |
Yajing Hou, Shuai Ge, Xiaowei Li, Cheng Wang, Huaizhen He, Langchong He |
| 27 |
[GO] |
2021―Jan―08 |
Expression of SARS-COV-2 cell receptor gene ACE2 is associated with immunosuppression and metabolic reprogramming in lung adenocarcinoma based on bioinformatics analyses of gene expression profiles |
Md. Nazim Uddin, Rehana Akter, Mengyuan Li, Zeinab Abdelrahman |
| 28 |
[GO] |
2020―Dec―11 |
Thermovaccination - thermoheliox as a stimulator of the immune response. Kinetics of the synthesis of antibodies and C-reactive protein in coronavirus infection |
Sergey D. Varfolomeev, Alexander A. Panin, Valeriy I. Bykov, Svetlana B. Tsybenova, Sergey V. Zhuravel, Anna M. Ryabokon, Irina I. Utkina, Pavel V. Gavrilov, Sergey S. Petrikov, Lyudmila V. Shogenova, Alexander G. Chuchalin |
| 29 |
[GO] |
2020―Dec―02 |
2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease |
Katrina L. Forrestall, Darcy E. Burley, Meghan K. Cash, Ian R. Pottie, Sultan Darvesh |
| 30 |
[GO] |
2020―Nov―09 |
In silico analysis of selected alkaloids against main protease (Mpro) of SARS-CoV-2 |
Saksham Garg, Arpita Roy |
| 31 |
[GO] |
2020―Oct―27 |
Race to arsenal COVID-19 therapeutics: Current alarming status and future directions |
Ankit Kumar Dubey, Aakansha Singh, Shardendu Prakash, Manoj Kumar, Ashok K. Singh |
| 32 |
[GO] |
2020―Oct―06 |
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19 |
Amjad Husain, Siddappa N. Byrareddy |
| 33 |
[GO] |
2020―Jul―28 |
Roles of flavonoids against coronavirus infection |
Maria Russo, Stefania Moccia, Carmela Spagnuolo, Idolo Tedesco, Gian Luigi Russo |
